NB. Metastatic non-renal cancer involving kidney 8-13% in some series. Enhancement and absence of other non-renal mets increases likelihood of primary RCC. In one series of 100 patients with primary extrarenal cancer and a lump in the kidney, 86% of
Leibovich (Mayo) Score •Pathological T stage 0-4 •Nodal status 0-2 •Tumour size –10cm 1 •Nuclear Grade 0-3 •Histological tumour necrosis 0-1 Scores from 0 –11 Low=0-2, Intermediate=3-5 & High=6 or more Leibovich et al; Cancer 2003
Renal Mass and Localized Renal Cancer: AUA Guideline focuses on the evaluation and management of clinically localized renal masses suspicious for …
• Monopodial & dipodial branching • Stephen’s Hypothesis and the “shared molecule hypothesis” The Central Mechanism of Kidney Development is the Conversion of Mesenchyme into Epithelia • MET: Kidney and Testis • EMT: Neural Crest, Endocardial cushion
chronic or acute kidney disease in veterinary medicine . In human medicine, a high correlation between cortical echogenicity and glomerular sclerosis, tubular
and symptoms (see chart below). The rate of decline in renal function and progression of chronic re-nal failure is related to the underlying disorder, the urinary excretion ... Thick, tenacious sputum Depressed cough reflex Pleuritic pain Shortness o
Looking for online definition of Renal impairment in the Medical Dictionary? Renal impairment explanation free. What is Renal impairment? Meaning of Renal impairment …
100 Invasive cancer confined to kidney cortex and/or medulla ^ * L L 200 Invasion of renal capsule Renal pelvis or calyces involved Separate focus of tumor in renal pelvis/calyx ^ * L L 300 Localized, NOS ^ * L L 310 Stated as T1a with no other infor
CASE REPORT Open Access Renal collecting duct carcinoma with extensive coagulative necrosis mimicking anemic infarct: report of a case and the literature review
Mutational analysis of EYA1 gene revealed a novel splice site mutation, c.1475+1G>C, that affects EYA1 splicing and produces an aberrant mRNA transcript, lacking exon 15, which is predicted to encode a truncated protein of 456 aa.
Kobayashi et al. BMC Urology (2018) 18:11 https://doi.org/10.1186/s12894-018-0324-9
Renal capsule metastasis from renal pelvic cancer: a case report Yasuyuki Kobayashi1* , Hiroki Arai1, Masahito Honda1, Takashi Matsumoto2 and Kyotaro Yoshida3
Abstract Background: Metastatic renal cancers are relatively common. Most are metastases to the renal parenchyma via a hematogenous route and are derived from lung, breast, and gastrointestinal cancer, malignant melanoma, and hematologic malignant cancer. However, little is known about renal capsule metastasis from other cancers. Case presentation: We report a 71-year-old woman with breast cancer who was treated with endocrine therapy. She presented with gross hematuria and was diagnosed as having right renal pelvic cancer and renal cell cancer. She underwent right laparoscopic radical nephroureterectomy. Pathological findings revealed right pelvic cancer and renal capsule metastasis. Conclusion: Renal capsule metastasis derived from renal pelvic cancer is very rare. When diagnosing renal capsule cancer, we believe that renal capsule metastasis should also be taken into consideration. Clinical and radiological differential diagnosis of renal capsule metastasis from renal cell cancer and primary renal capsule cancer is difficult. Assessment of the histopathological findings of the surgical specimens seems to be the only realistic approach to achieving the correct diagnosis. Keywords: Breast cancer, Renal capsule metastasis, Renal cell cancer, Renal pelvic cancer, Urothelial carcinoma
Background Metastatic renal cancer is relatively common and is mainly derived from lung, breast, and gastrointestinal cancer, malignant melanoma, and hematologic malignant cancer [1–4]. Almost all of the metastases are to the renal parenchyma, and to our best knowledge, there is no case report describing metastasis to the renal capsule. We report a rare case of renal capsule metastasis derived from renal pelvic cancer. Case presentation A 71-year-old woman was diagnosed as having breast cancer (left breast, invasive lobular carcinoma, T4cN3cM1, Stage IV) in September 2014 and was treated with endocrine therapy (exemestane 25 mg/day). Gross hematuria was pointed out in January 2015, and hematuria was detected by urinalysis. Her past history included hypertension and diabetes mellitus but no history of smoking. Urinary cytology was Class III (Papanicolaou classification) . * Correspondence: [email protected] 1 Departments of Urology, Kinki Central Hospital of Mutual Aid Association of Public Teachers, 3-1 Kurumazuka, Itami, Hyogo 664-8533, Japan Full list of author information is available at the end of the article
Blood tests showed a hemoglobin of 12.0 g/dL, serum creatinine of 0.87 mg/dL, lactate dehydrogenase of 251 U/ L, aspartate aminotransferase of 18 U/L, and alanine aminotransferase of 6 U/L. Computed tomography (CT) showed a hypovascular mass 25 mm diameter in the right renal pelvis and a hypervascular mass of 22 mm in diameter in the upper pole of the right kidney. The hypervascular mass showed a contrast effect in the early phase. There were no signs of metastasis in the lung, liver, or abdominal lymph nodes. A retrograde pyelogram showed a filling defect in the right renal pelvis, and catheterized urine cytology was class III (Papanicolaou classification). No obvious findings were observed on radiographic imaging of the ureter. We diagnosed her as having right renal pelvic cancer (cT3N0M0) and right renal cell cancer (cT1aN0M0). Because her metastatic breast cancer prognosis was expected to be relatively good, she thus underwent right laparoscopic radical nephroureterectomy via a retroperitoneal approach. As described below, we diagnosed right pelvic cancer and renal capsule metastasis. Macroscopically, the renal pelvic tumor was 4 cm in diameter, yellowish white, and soft. It was located in the right renal pelvis and infiltrated into the parenchyma.
Fig. 1 Gross appearance of the right kidney. a Renal pelvic cancer occupying the renal pelvis and invading the renal parenchyma (arrows). b The renal capsule cancer coating the renal capsule was easily peeled off from the renal parenchyma (arrows)
The other renal tumor was 2.5 cm in diameter, wellcircumscribed, yellowish white, and hard (Fig. 1). It was coated with renal capsular tissue and was easily decapsulated from the renal parenchyma. This tumor was considered to be a renal capsule tumor. The ureteral wall was thickened, but its mucosa was normal. Microscopically, the renal pelvic tumor invaded the parenchyma but not the capsule beyond the parenchyma. The renal capsule tumor was circumscribed by the renal capsule and did not invade neighboring tissue. Both tumor cells were similar and had eosinophilic cytoplasm, round nuclei, and an alveolar pattern of growth, and they were concordant with urothelial carcinoma. Tumor cells of the ureter had eosinophilic cytoplasm, round nuclei, and a trabecular pattern of growth similar to those of the breast cancer cells. Immunohistochemically, the cancer cells of the renal pelvis were similar to those of the renal capsule (Fig. 2),
whereas the cancer cells of the ureter were similar to those of the breast cancer (Table 1). We concluded that the renal capsule cancer was derived from the renal pelvic cancer, and the ureter cancer was derived from the breast cancer. We thus diagnosed right pelvic cancer (urothelial carcinoma, G2 > G3, pT3) and renal capsule metastasis. We explained the necessity of adjuvant chemotherapy for the metastatic renal pelvic cancer to the patient, but she rejected chemotherapy and continued only with endocrine therapy. She then developed bilateral pleural effusions, mediastinal lymph node metastasis, para-aortic lymph node metastasis, and liver metastasis. She underwent a thoracentesis in October 2015, and the pleural effusion cytology was class V (Papanicolaou classification), compatible with breast cancer. Endocrine therapy was changed to letrozole 2.5 mg, but she died of breast cancer progression in January 2016.
Fig. 2 Histopathologic examination of the renal pelvic cancer and renal capsule cancer. a Hematoxylin and eosin (H&E)-stained section of the pelvic cancer. b H&E-stained section of the renal capsule cancer. c HER2-stained section of the pelvic cancer showing positive staining. d HER2-stained section of the renal capsule cancer showing positive staining
Kobayashi et al. BMC Urology (2018) 18:11
Page 3 of 4
Table 1 Immunohistochemical examination HER2
Renal pelvic cancer
Renal capsule cancer
HER human epidermal growth factor receptor 2, ER estrogen receptor, CK cytokeratin
Discussion Metastatic renal cancer is relatively common, and autopsy studies indicate that 12% of patients who die of cancer have renal metastasis . Mostly, the metastases are to the renal parenchyma, and few are to the renal capsule. Most renal metastases develop via a hematogenous route and are derived from lung, breast, and gastrointestinal carcinoma, malignant melanoma, and hematologic malignant cancer [1–4]. Renal metastasis is generally accompanied by systemic metastasis, and renal metastatic lesions are often small and multifocal . The renal capsule is a fibrous membrane that surrounds the renal parenchyma and can be separated from the renal parenchyma . Primary renal capsule cancer is relatively rare. It originates from renal capsule structures and is derived from mesenchymal components, and almost all renal capsule cancer is sarcoma such as leiomyosarcoma . Because high-grade renal sarcoma often grows rapidly, it is difficult to distinguish from sarcomatoid RCC in the clinical presentation and radiographic findings. The clinical presentation of renal sarcoma is similar to that of rapidly growing RCC, i.e., a palpable mass, abdominal or flank pain, and hematuria. In patients with renal capsule cancer, renal sarcoma should also be considered . Wide local excision with negative margins is desirable in the case of localized renal sarcoma because the most important prognostic factors for renal sarcoma are margin status and tumor grade . Contrastingly, metastatic renal capsule cancer is very rare and has never been reported in detail. The HER2 gene is an oncogene that has a similar structure to the epidermal growth factor receptor gene. Overexpression of HER2 protein occurs in 20% of patients with breast cancer and 13.5% of patients with upper urinary tract urothelial carcinoma [10, 11]. In the present patient, we concluded that the renal capsule metastasis was derived from the HER2-positive renal pelvic cancer, and the ureteral metastasis was derived from the HER2-negative breast cancer. Ureter metastasis derived from breast cancer was reported in 7.8% of patients with disseminated breast cancer in an autopsy series  and can cause ureteral obstruction and renal insufficiency. It occurs in long-
standing hormonal-dependent breast cancer with bone metastasis. The prognosis after diagnosis is relatively poor . However, 8 of 15 (53%) patients with ureter metastasis derived from breast cancer did not show any clinical findings of ureteral obstruction . The present patient did not have right hydronephrosis at surgery. During the preoperative assessment of this patient, we diagnosed her renal capsule cancer as renal cell cancer because it was solitary and showed a contrast effect in the early phase of CT. Based on the pathological findings, we concluded that the renal capsule cancer was derived from the renal pelvic cancer.
Conclusion Renal capsule metastasis derived from renal pelvic cancer is very rare. When diagnosing renal capsule cancer, we believe that renal capsule metastasis should also be taken into consideration. Clinical and radiological differential diagnosis of renal capsule metastasis from renal cell cancer and primary renal capsule cancer is difficult. For this reason, assessment of the histopathological findings of the surgical specimens seems to be the only realistic approach to achieving the correct diagnosis. Abbreviation CT: Computed tomography Acknowledgments The authors thank the members of the ethics committee who reviewed the contents of the present study. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Availability of data and materials The authors presented the essential data within the manuscript. Authors’ contributions YK drafted the manuscript and was responsible for critical revision of the manuscript. YK, HA, and MH performed the operation. YK and TM made substantial contributions to patient management. TM made substantial contributions to analysis and interpretation of data. YK and KY analyzed the patient data. YK was responsible for the conception and design of this study and interpretation of the data. All authors read and approved the final manuscript. Ethics approval and consent to participate This report was approved by the Ethics committee of the Kinki Central Hospital of Mutual Aid Association of Public Teachers. Consent for publication Written informed consent was obtained from the patient for publication of this manuscript. Competing interests The authors declare that they have no competing interests.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Kobayashi et al. BMC Urology (2018) 18:11
Page 4 of 4
Author details 1 Departments of Urology, Kinki Central Hospital of Mutual Aid Association of Public Teachers, 3-1 Kurumazuka, Itami, Hyogo 664-8533, Japan. 2Surgery, Kinki Central Hospital of Mutual Aid Association of Public Teachers, 3-1 Kurumazuka, Itami, Hyogo 664-8533, Japan. 3Pathology, Kinki Central Hospital of Mutual Aid Association of Public Teachers, 3-1 Kurumazuka, Itami, Hyogo 664-8533, Japan. Received: 30 June 2017 Accepted: 21 February 2018
References 1. Choyke PL, White EM, Zeman RK, Jaffe MH, Clark LR. Renal metastases: clinicopathologic and radiologic correlation. Radiology. 1987;162:359–63. 2. Pollack HM, Banner MP, Amendola MA. Other malignant neoplasms of the renal parenchyma. Semin Roentgenol. 1987;22:260–74. 3. Aron M, Nair M, Hemal AK. Renal metastasis from primary hepatocellular carcinoma. A case report and review of the literature. Urol Int. 2004;73:89–91. 4. Stage AC, Pollock RE, Matin SF. Bilateral metastatic renal synovial sarcoma. Urology. 2005;65:389. 5. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945;101:51920. 6. Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM. Hereditary renal cancers. Radiology. 2003;226:33–46. 7. Zhu G, Wu D, Wu K, Song W, Yang Z, Zhang Y, et al. The retroperitoneal laparoscopic renal capsulectomy for spontaneous renal subcapsular fluid collection: a case-series report and literature review. Medicine (Baltimore). 2016;95:e3751. 8. Wang X, Xu R, Yan L, Zhuang J, Wei B, Kang D, et al. Adult renal sarcoma: clinical features and survival in a series of patients treated at a high-volume institution. Urology. 2011;77:836–41. 9. Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2015. p. 1360–4. 10. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291:1972–7. 11. Sasaki Y, Sasaki T, Kawai T, Morikawa T, Matsusaka K, Kunita A, et al. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients. Int J Clin Exp Pathol. 2014;7:699–708. 12. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950;3:74–85. 13. Recloux P, Weiser M, Piccart M, Sculier JP. Ureteral obstruction in patients with breast cancer. Cancer. 1988;61:1904–7. 14. Geller SA, Lin C. Ureteral obstruction from metastatic breast carcinoma. Arch Pathol. 1975;99:476–8.
Submit your next manuscript to BioMed Central and we will help you at every step: • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal • We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visibility for your research Submit your manuscript at www.biomedcentral.com/submit